drugset / Trial / NCT06055244

Amantadine Therapy for Cognitive Impairment in Long COVID

NCT06055244

Phase 2 Completed 64 enrolled Ohio State University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.

Timeline

Start
2023-12-07
Primary completion
2025-12-11
Completion
2025-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Amantadine Unknown 100 mg

Indications